• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

DNA binding domain mutational status and rituximabbased treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification.

作者信息

Martire Gaia, Lovisa Federica, Carraro Elisa, Rizzato Domenico, Cesaro Simone, Mura Rosa Maria, Tondo Annalisa, Bertolin Cinzia, Boaretto Francesca, Salviati Leonardo, Biffi Alessandra, Pillon Marta, Mussolin Lara

机构信息

Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy; Paediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padova University and University Hospital, Padova.

Istituto di Ricerca Pediatrica Città della Speranza, Padova.

出版信息

Haematologica. 2024 Sep 1;109(9):3031-3036. doi: 10.3324/haematol.2023.284868.

DOI:10.3324/haematol.2023.284868
PMID:38385281
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11367192/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aba/11367192/b6f93193d376/1093031.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aba/11367192/04b0db55f2ba/1093031.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aba/11367192/b6f93193d376/1093031.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aba/11367192/04b0db55f2ba/1093031.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aba/11367192/b6f93193d376/1093031.fig2.jpg

相似文献

1
DNA binding domain mutational status and rituximabbased treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification.DNA结合域突变状态和基于利妥昔单抗的治疗是小儿伯基特淋巴瘤患者分层的独立预后因素。
Haematologica. 2024 Sep 1;109(9):3031-3036. doi: 10.3324/haematol.2023.284868.
2
[Clinical and prognostic analysis of 186 children with Burkitt's lymphoma].186例伯基特淋巴瘤患儿的临床与预后分析
Zhonghua Er Ke Za Zhi. 2018 Aug 2;56(8):605-610. doi: 10.3760/cma.j.issn.0578-1310.2018.08.010.
3
Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08.染色体异常可能与儿童和青少年伯基特/伯基特样淋巴瘤的预后相关：儿童癌症研究组CCG-E08研究报告
J Pediatr Hematol Oncol. 2004 Mar;26(3):169-78. doi: 10.1097/00043426-200403000-00006.
4
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.TP53 基因突变谱及对 R-CHOP 治疗弥漫性大 B 细胞淋巴瘤患者的预后意义：国际弥漫性大 B 细胞淋巴瘤利妥昔单抗-CHOP 协作组研究报告。
Blood. 2012 Nov 8;120(19):3986-96. doi: 10.1182/blood-2012-05-433334. Epub 2012 Sep 5.
5
The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.基因组失衡的存在与接受包括利妥昔单抗在内的剂量密集化疗的伯基特淋巴瘤患者的不良预后相关。
Br J Haematol. 2016 Feb;172(3):428-38. doi: 10.1111/bjh.13849. Epub 2015 Nov 16.
6
Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma.KLF4的表达是儿童伯基特淋巴瘤生存的预测标志物。
Leuk Lymphoma. 2014 Aug;55(8):1806-14. doi: 10.3109/10428194.2013.848437. Epub 2014 Feb 6.
7
Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol.采用AIEOP LNH - 97方案治疗的伯基特淋巴瘤和弥漫性大B细胞淋巴瘤儿童及青少年患者预后因素的检测
Br J Haematol. 2016 Nov;175(3):467-475. doi: 10.1111/bjh.14240. Epub 2016 Jul 8.
8
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.利妥昔单抗联合化疗治疗中枢神经系统和/或骨髓阳性的儿童及青少年伯基特淋巴瘤/白血病：儿童肿瘤学组报告
Br J Haematol. 2014 Nov;167(3):394-401. doi: 10.1111/bjh.13040. Epub 2014 Jul 26.
9
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.接受剂量调整的EPOCH-R方案治疗的成年伯基特淋巴瘤患者的预后因素
Blood Adv. 2023 Sep 26;7(18):5320-5324. doi: 10.1182/bloodadvances.2023010223.
10
[Burkitt lymphoma, a diagnostic emergency].[伯基特淋巴瘤，一种诊断紧急情况]
Rev Prat. 2016 Jan;66(1):79-82.

引用本文的文献

1
Dedicated diagnostic approaches for mature B-cell non-Hodgkin lymphomas occurring in children, adolescents, and young adults.针对儿童、青少年和青年中发生的成熟B细胞非霍奇金淋巴瘤的专用诊断方法。
Histopathology. 2025 Jan;86(1):17-37. doi: 10.1111/his.15362. Epub 2024 Nov 20.
2
binding domain mutations are bad news in Burkitt lymphoma.结合结构域突变在伯基特淋巴瘤中是个坏消息。
Haematologica. 2024 Sep 1;109(9):2775-2777. doi: 10.3324/haematol.2024.285213.

本文引用的文献

1
Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.伯基特淋巴瘤的分子特征的临床相关性随年龄而异。
Nat Commun. 2022 Jul 6;13(1):3881. doi: 10.1038/s41467-022-31355-8.
2
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma.TP53 基因组异常可明确界定儿科 B 细胞非霍奇金淋巴瘤的不同危险分组。
Leukemia. 2022 Mar;36(3):781-789. doi: 10.1038/s41375-021-01444-6. Epub 2021 Oct 21.
3
Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations.
639例儿童及青少年复发性非霍奇金淋巴瘤的治疗与转归分析及治疗建议
Cancers (Basel). 2021 Apr 25;13(9):2075. doi: 10.3390/cancers13092075.
4
Targeting p53 for the treatment of cancer.以p53为靶点治疗癌症。
Semin Cancer Biol. 2022 Feb;79:58-67. doi: 10.1016/j.semcancer.2020.07.005. Epub 2020 Jul 31.
5
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.利妥昔单抗治疗高危、成熟 B 细胞非霍奇金淋巴瘤患儿。
N Engl J Med. 2020 Jun 4;382(23):2207-2219. doi: 10.1056/NEJMoa1915315.
6
Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents.非霍奇金淋巴瘤治疗后的第二恶性肿瘤：189 例儿童和青少年的回顾性跨国研究。
Leukemia. 2021 Feb;35(2):534-549. doi: 10.1038/s41375-020-0841-x. Epub 2020 May 11.
7
Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration.采用AIEOP LNH - 97方案治疗并接受或未接受抗CD20治疗的儿童成熟B细胞白血病/淋巴瘤的微小残留病分析
Br J Haematol. 2020 May;189(3):e108-e111. doi: 10.1111/bjh.16531. Epub 2020 Feb 20.
8
Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study.当代伯基特淋巴瘤治疗成熟 B 细胞非霍奇金淋巴瘤的晚期健康结局：来自儿童癌症幸存者研究的报告。
J Clin Oncol. 2019 Oct 1;37(28):2556-2570. doi: 10.1200/JCO.19.00525. Epub 2019 Jul 8.
9
Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol.采用AIEOP LNH - 97方案治疗的伯基特淋巴瘤和弥漫性大B细胞淋巴瘤儿童及青少年患者预后因素的检测
Br J Haematol. 2016 Nov;175(3):467-475. doi: 10.1111/bjh.14240. Epub 2016 Jul 8.
10
Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.利妥昔单抗联合化疗治疗中枢神经系统和/或骨髓阳性的儿童及青少年伯基特淋巴瘤/白血病：儿童肿瘤学组报告
Br J Haematol. 2014 Nov;167(3):394-401. doi: 10.1111/bjh.13040. Epub 2014 Jul 26.